Earnings summaries and quarterly performance for HeartSciences.
Research analysts covering HeartSciences.
Recent press releases and 8-K filings for HSCS.
HeartSciences Inc. extends loan maturity, raises capital, and converts debt
HSCS
Debt Issuance
Convertible Preferred Issuance
New Projects/Investments
- HeartSciences Inc. and Front Range Ventures LLC entered into Amendment No. 7 to their Loan and Security Agreement and a No. 3 Amended and Restated Secured Promissory Note on September 26, 2025, extending the maturity date of the $500,000 loan to September 30, 2026, with an interest rate of 12% per annum, compounded annually.
- As of October 1, 2025, the company received $6.7 million in gross proceeds from its Regulation A Offering, resulting in the issuance of 1,912,383 Units.
- Also as of October 1, 2025, HeartSciences Inc. completed a debt exchange, converting $2,060,000 in principal and $45,000 of accrued interest from an unsecured promissory note into 597,578 shares of common stock.
- Following these transactions, there are 3,069,635 shares of common stock issued and outstanding as of October 1, 2025.
Oct 1, 2025, 9:23 PM
HeartSciences Reports Q1 2026 Financial Results and Business Updates
HSCS
Earnings
Product Launch
New Projects/Investments
- HeartSciences Inc. reported no meaningful revenue for the first quarter of fiscal 2026, which ended July 31, 2025.
- As of July 31, 2025, the company had approximately $2.8 million in cash and cash equivalents and $3.1 million in shareholders’ equity.
- The company successfully launched its MyoVista Insights™ software platform and received an FDA Breakthrough Device Designation for its aortic stenosis ECG algorithm.
- Subsequent to the quarter, HeartSciences strengthened its balance sheet by raising an additional $0.8 million through a Reg A+ offering and converting $0.7 million of debt into equity.
Sep 11, 2025, 8:28 PM
HeartSciences Reports FQ1 2026 Financial Results and Business Updates
HSCS
Earnings
Product Launch
New Projects/Investments
- HeartSciences reported no meaningful revenue for the first quarter of fiscal 2026, which ended July 31, 2025. As of that date, the company had approximately $2.8 million in cash and cash equivalents, and $3.1 million in shareholders’ equity.
- Subsequent to FQ1 2026, HeartSciences raised an additional $0.8 million through its Reg A+ offering and exchanged $0.7 million of debt into equity.
- The company successfully launched MyoVista Insights, a cloud-native software platform designed for AI-ECG algorithms, and received FDA Breakthrough Device Designation for its aortic stenosis ECG algorithm.
- CPT reimbursement codes are now in place for AI-ECG, covering algorithms provided by MyoVista Insights, which is expected to support AI-ECG adoption.
Sep 11, 2025, 8:15 PM
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more